Skip to site menu Skip to page content

Daily Newsletter

22 July 2025

Daily Newsletter

22 July 2025

ARCHIMED to acquire life sciences company ZimVie for $730m

ZimVie’s board of directors granted unanimous approval for the transaction, anticipated to be finalised by the end of this year.

Prasanna Gullapalli July 22 2025

Healthcare investment company ARCHIMED’s affiliate is set to acquire ZimVie, a life sciences company focusing on the dental implant market, for an enterprise value of around $730m.

According to the definitive agreement signed by the companies, the stockholders of ZimVie will be entitled to a $19.00 cash payment for each outstanding share when the transaction is finalised.

The price per share signifies a premium of 99% to ZimVie's 90-day volume-weighted average share price, which stands at $9.57.

ZimVie’s Board of Directors granted unanimous approval for the transaction, anticipated to be finalised by the end of this year.

This is contingent on standard closing conditions, including ZimVie's stockholders' and regulatory bodies' approval. Notably, the agreement is not dependent on financing.

ARCHIMED managing partner André-Michel Ballester said: “We’re excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”

Following the acquisition, ZimVie is set to become a private entity. Additionally, ZimVie, with Centerview Partners' assistance, may seek alternative proposals for a 40-day period ending on 29 August 2025, although there is no certainty of a superior offer emerging.

ZimVie CEO and board chairman Vafa Jamali said: “This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years.

“Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”

Centerview Partners is acting as ZimVie's exclusive financial adviser, with Cravath, Swaine & Moore as its legal adviser.

Meanwhile, UBS Investment Bank and Latham & Watkins are serving as ARCHIMED’s financial and legal advisers, respectively.

In 2023, the US Food and Drug Administration (FDA) cleared ZimVie’s spinal fixation system, Vital, for use with Brainlab’s surgical imaging, planning, and navigation tools.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close